[HTML][HTML] The role of the microbiota in the diabetic peripheral artery disease
F Biscetti, E Nardella, AL Cecchini, R Landolfi… - Mediators of …, 2019 - hindawi.com
… Indeed, the presence of Chlamydia pneumoniae in blood and … introduce new therapeutic
solutions against the in-stent restenosis… , “Rapamycin can inhibit the development of Chlamydia …
solutions against the in-stent restenosis… , “Rapamycin can inhibit the development of Chlamydia …
[HTML][HTML] A new therapeutic candidate for cardiovascular diseases: Berberine
Y Cai, Q Xin, J Lu, Y Miao, Q Lin, W Cong… - Frontiers in …, 2021 - frontiersin.org
… In-stent restenosis and neoatherosclerosis after … BBR (50 µmol/L) inhibited chlamydia
pneumoniae infection … that by inhibiting the activity of the mammalian target of rapamycin (mTOR) …
pneumoniae infection … that by inhibiting the activity of the mammalian target of rapamycin (mTOR) …
[PDF][PDF] Profiling Antichlamydial Compounds in Monocyte and Macrophage Cell Models
M Kortesoja - 2020 - helda.helsinki.fi
… Chlamydia was developed. Later, when cell culture methods for … In this work, only the name
Chlamydia pneumoniae is used. … An inclusion can also be released from the cell only partly …
Chlamydia pneumoniae is used. … An inclusion can also be released from the cell only partly …
[HTML][HTML] Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics
… Similarly, BBR attenuated Chlamydia pneumoniae infection-… /Akt/mammalian target of
rapamycin (mTOR) signaling pathway … in neovascular atherosclerosis and in-stent restenosis 94 . …
rapamycin (mTOR) signaling pathway … in neovascular atherosclerosis and in-stent restenosis 94 . …
Early Growth Response-1: Friend or Foe in the Heart?
… Chlamydia pneumoniae is known to induce atherosclerotic inflammation, pro-… was partially
reversed by the autophagy inhibitor 3-MA. The double-edged sword nature of autophagy may …
reversed by the autophagy inhibitor 3-MA. The double-edged sword nature of autophagy may …
Large-vessel vasculitis
D Pugh, M Karabayas, N Basu, MC Cid… - Nature Reviews …, 2021 - nature.com
… , which will inform the development of increasingly … varicella-zoster virus, Chlamydia
pneumoniae, Mycoplasma spp. … ), and mammalian target of rapamycin (mTOR) signalling …
pneumoniae, Mycoplasma spp. … ), and mammalian target of rapamycin (mTOR) signalling …
[PDF][PDF] Persistent Symptomatology: A Case of Celiac Disease with underlying Crohn's Disease
DO Ermal Hasalliu - acponline.org
… , and angiography can help define the anatomy of partial … 0.4-0.6% in patients who have
sirolimus drug eluting stent [3] . The … Multiple case reports were published in the past for in-stent …
sirolimus drug eluting stent [3] . The … Multiple case reports were published in the past for in-stent …
Combating atherosclerosis with nanodrug delivery approaches: from bench side to commercialization
… , leading to thrombosis that can partly or entirely block the … , sirolimus, biolimus, everolimus,
etc.) may be used for … containing liposomes effectively inhibited in-stent neointimal growth in …
etc.) may be used for … containing liposomes effectively inhibited in-stent neointimal growth in …
[HTML][HTML] MYC: there is more to it than cancer
MF Zacarías-Fluck, L Soucek… - Frontiers in Cell and …, 2024 - frontiersin.org
… and acinar development were impaired at birth, but partially … While inhibition of mTORC1
by rapamycin prior to RANKL … to the inhibition of SMC proliferation as a way of preventing …
by rapamycin prior to RANKL … to the inhibition of SMC proliferation as a way of preventing …
[图书][B] Recent Advancement in Therapeutic Use of Chemical Compounds and Drug Delivery
BC Samanta, N Sutradhar - 2021 - books.google.com
… The nanoscience and nanotechnology may be one of the tools for the development of a …
aid in preventing drugs from being tarnished in the gastrointestinal region and help the delivery …
aid in preventing drugs from being tarnished in the gastrointestinal region and help the delivery …